A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine - PIONEER-PEDS2

What is the goal of the study?

This is a prospective, randomized, open-label, 12-month study in children and adolescents with a diagnosis of migraine who previously enrolled in and completed Study H8H-MC-LAHX (LAHX) or Study H8H-MC-LAHV (LAHV). Study participants will be stratified by age group (6 to <12 years and 12 to><18 years based on age at time of enrollment into study lahx or lahv and randomized in a 1:1 ratio to treatment with weight-based doses comparable to 100 mg and 200 mg adult exposure.>

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

• PI (Study Doctor): Heidi Blume
• Study Team Member: Jacqueline Lee-Eng, [email protected]